Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

Oncotarget

Volumn 6, Issue 29, 2015, Pages 28173-28182

  Triulzi, Tiziana ^a   Cecco, Loris De ^a   Sandri, Marco ^a   Prat, Aleix ^b,c   Giussani, Marta ^a   Paolini, Biagio ^a   Carcangiu, Marialuisa L ^a   Canevari, Silvana ^a   Bottini, Alberto ^d   Balsari, Andrea ^a,e   Menard, Sylvie ^a   Generali, Daniele ^d   Campiglio, Manuela ^a   Cosimo, Serena Di ^a   Tagliabue, Elda ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d CREMONA HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Gene expression profiling; Lymphocytes; Trastuzumab benefit

Indexed keywords

CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOINFORMATICS; BREAST BIOPSY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ERBB2 GENE; ESR1 GENE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LOW RISK POPULATION; MIDDLE AGED; NONBIOLOGICAL MODEL; PAM50 CLASSIFICATION; PATIENT IDENTIFICATION; PREDICTIVE VALUE; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSCRIPTOMICS; TRASTUZUMAB RISK PREDICTION MODEL; VALIDATION PROCESS; WHOLE TRANSCRIPTOME ANALYSIS; ADJUVANT CHEMOTHERAPY; BIOLOGICAL MODEL; BREAST NEOPLASMS; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; DNA MICROARRAY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; KAPLAN MEIER METHOD; METABOLISM; NEOADJUVANT THERAPY; PROGNOSIS; RISK FACTOR; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MODELS, GENETIC; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RISK FACTORS; TRASTUZUMAB;

EID: 84944463329     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4405     Document Type: Article

References (32)

1. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012; 4:CD00623.
2. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32:3744-3752.
3. Pinto AC, Ades F, De AE, Piccart-Gebhart M. Trastuzumab for patients with HER positive breast cancer: delivery, duration and combination therapies. Breast. 2013; 22:S152-5.
4. Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, et al. Predicting degree of benefit from adjuvant trastuzumab in NSABP Trial B-31. J Natl Cancer Inst. 2013; 105:1782-1788.
5. Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, Gomez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res. 2014; 20:511-521.
6. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, et al. Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25:1544-1550.
7. Perez EA, Thompson A, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial. J Clin Oncol. 2015; 33:701-708.
8. De Cecco L, Bossi P, Locati L, Canevari S, Licitra L. Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. Ann Oncol. 2014; 25:1628-1635.
9. Koukourakis MI, Giatromanolaki A, Bottini A, Cappelletti MR, Zanotti L, Allevi G, Strina C, Ardine M, Milani M, Brugnoli G, Martinotti M, Ferrero G, Bertoni R, et al. Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy. Br J Cancer. 2014; 110:2209-2216.
10. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009; 11:R15.
11. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol. 2004; 2:E108.
12. Nahta R, O'Regan RM. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat. 2012; 135:39-48.
13. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA. 2011; 108:7142-7147.
14. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu YX. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010; 18:160-170.
15. Casey SC, Bellovin DI, Felsher DW. Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol. 2013; 25:246-258.
16. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008; 8:59-73.
17. Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, Fabi A, Aiello R, Riccardi F, Valle E, Scotti V, Tabaro G, Giuffrida D, et al. Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Res Treat. 2013; 141:101-110.
18. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van EF, Rouas G, Francis P, Crown JP, Hitre E, De AE, Quinaux E, Di LA, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013; 31:860-867.
19. Ravo M, Mutarelli M, Ferraro L, Grober OM, Paris O, Tarallo R, Vigilante A, Cimino D, De BM, Nola E, Cicatiello L, Weisz A. Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. Lab Invest. 2008; 88:430-440.
20. R Development Core Team. (2007). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. http://www.R-project.org.
21. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5:R80.
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005; 102:15545-15550.
23. Yasrebi H. SurvJamda: an R package to predict patients' survival and risk assessment using joint analysis of microarray gene expression data. Bioinformatics. 2011; 27:1168-1169.
24. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56:337-344.
25. Fountzilas E, Kotoula V, Angouridakis N, Karasmanis I, Wirtz RM, Eleftheraki AG, Veltrup E, Markou K, Nikolaou A, Pectasides D, Fountzilas G. Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer. PLoS ONE. 2013; 8:e70429.
26. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007; 8:118-127.
27. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature. 2012; 486:346-352.
28. Gluck S, Ross JS, Royce M, McKenna EF Jr, Perou CM, Avisar E, Wu L. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/-trastuzumab. Breast Cancer Res Treat. 2012; 132:781-791.
29. de Ronde JJ, Rigaill G, Rottenberg S, Rodenhuis S, Wessels LF. Identifying subgroup markers in heterogeneous populations. Nucleic Acids Res. 2013; 41:e200.
30. Du P, Kibbe WA, Lin SM. Lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008; 24:1547-1548.
31. Stacklies W, Redestig H, Scholz M, Walther D, Selbig J. pcaMethods -a bioconductor package providing PCA methods for incomplete data. Bioinformatics. 2007; 23:1164-1167.
32. Cox DR, Oakes D. Analysis of Survival Data. Chapman and HallLondon: 1984.